Healthcare


Technologies Driving Precision Medicine

Emerging Role of Chimeric Antigen Receptor (CAR) T-cell Treatment and Bispecific/Multi-specific T-cell Engaging Antibody Therapies
Share this:
     
Published: 26 Sep 2017

Targeted and personalized therapeutics are likely to transform the existing precision medicine landscape. With recent landmark regulatory approval, CAR T therapy has the potential to emerge as the industry standard for cancer management in the future and potentially replace existing treatment techniques. Bispecific and multi-specific antibody platforms are likely to emerge as the preferred alternatives for existing monotherapy strategies as they offer increased therapeutic efficacy, while reducing off-target effects. This global research service provides comprehensive insights across key technologies, research trends, funding IP outlook, clinical trials and industry innovations that are likely to transform the landscape of chimeric antigen receptor (CAR) T cell and bispecific/multi-specific T cell engaging immunotherapies.

  1.  
  2.  
  3.  
  4.  
  5.  
  6.  
  7.  
  8.  
  9.  

Tools

Features of this research

SUBSCRIPTIONS

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..